Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant    ý    Filed by a Party other than the Registrant    ¨
Check the appropriate box:
¨
Preliminary Proxy Statement
¨
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨
Definitive Proxy Statement
¨
Definitive Additional Materials
ý
Soliciting Material under Rule 14a-12
PDL BioPharma, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Payment of Filing Fee (Check the appropriate box):
ý
No fee required.
¨
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
 
(1) Title of each class of securities to which transaction applies:
 
(2) Aggregate number of securities to which transaction applies:
 
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
 
(4) Proposed maximum aggregate value of transaction:
 
(5) Total fee paid:
¨
Fee paid previously with preliminary materials.
¨
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 
(1) Amount previously paid:
 
(2) Form, Schedule or Registration Statement No.:
 
(3) Filing Party:
 
(4) Date Filed:





 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 15, 2020

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)
Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)

932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)
(775) 832-8500
(Company’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
ý    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.01 per share
PDLI
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨
 





Item 7.01 Regulation FD Disclosure.

Beginning on January 15, 2020, PDL BioPharma, Inc. (the “Company”) will participate in conferences with investors. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Presentation

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s products, other assets or business are disclosed in the “Risk Factors” contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2019, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ Dominique Monnet
 
 
Dominique Monnet
 
 
President and Chief Executive Officer




Dated: January 15, 2020







































Exhibit Index


Exhibit No.
 
Description
99.1
 
Presentation






https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide1b16.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide2b15.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide3b15.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide4b15.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide5b15.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide6b15.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide7b15.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide8b13.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slide9b12.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx79.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx80.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx81.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx82.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx83.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx84.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx85.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx86.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx87.jpg





https://cdn.kscope.io/eb1c2eed6659ea11773d2d8082018431-slidx88.jpg